McKesson Corporation (NYSE:MCK – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seventeen analysts that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $960.5333.
A number of equities analysts have recently issued reports on MCK shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $875.00 target price on shares of McKesson in a research note on Friday, May 8th. Weiss Ratings lowered McKesson from a “buy (b+)” rating to a “buy (b)” rating in a report on Monday, May 18th. Wells Fargo & Company cut their price objective on McKesson from $925.00 to $812.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Barclays reduced their target price on McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Finally, William Blair initiated coverage on shares of McKesson in a research report on Tuesday, April 28th. They set an “outperform” rating on the stock.
Check Out Our Latest Report on MCK
Insider Activity at McKesson
Institutional Trading of McKesson
Several large investors have recently bought and sold shares of the company. University of Texas Texas AM Investment Management Co. acquired a new stake in McKesson in the 4th quarter valued at about $25,000. Swiss RE Ltd. acquired a new position in McKesson during the fourth quarter worth about $26,000. State of Wyoming acquired a new position in McKesson during the second quarter worth about $29,000. Board of the Pension Protection Fund purchased a new stake in shares of McKesson in the fourth quarter valued at about $33,000. Finally, Kingdom Financial Group LLC. acquired a new stake in shares of McKesson in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 85.07% of the company’s stock.
McKesson Stock Performance
Shares of McKesson stock opened at $786.17 on Tuesday. McKesson has a one year low of $637.00 and a one year high of $999.00. The company has a market cap of $92.05 billion, a P/E ratio of 20.44, a PEG ratio of 1.29 and a beta of 0.31. The firm has a fifty day moving average of $769.23 and a two-hundred day moving average of $838.98.
McKesson (NYSE:MCK – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.56 by $0.13. The business had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, equities analysts predict that McKesson will post 44.28 earnings per share for the current year.
McKesson Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Investors of record on Monday, June 1st were paid a $0.82 dividend. The ex-dividend date was Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 8.53%.
About McKesson
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Featured Articles
- Five stocks we like better than McKesson
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil JalapeƱo: An Early Step to Massive AI Growth Potential
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
